Navigation Links
Beckman Coulter to Acquire Lab-Based Diagnostics Business From Olympus Corporation
Date:2/26/2009

trates our commitment to further expand chemistry and sustain our above-market growth in immunoassay. A foundation of stable markets, a defensive business model, well-recognized competencies in optimizing lab processes and an unyielding commitment to quality positions us for continued leadership in biomedical testing," Garrett concluded.

This transaction is expected to close in the third quarter of 2009 and is subject to customary government approvals, the finalization of certain ancillary agreements and the disclosure schedules, as well as other customary conditions.

Advisors

Morgan Stanley is acting as financial advisor and Latham & Watkins, LLP is serving as legal counsel to Beckman Coulter in connection with this transaction.

Investor Webcast Event

Beckman Coulter will host a webcast on Friday, February 27, 2009 at 5:00 AM Pacific time to discuss the transaction. The audio portion of the event may be accessed by dialing (877) 516-3365 or (706) 679-3246 and asking for the Beckman Coulter conference call or reservation #87537521.

To participate via the website and obtain access to the presentation materials, please go to Beckman Coulter's website at www.beckmancoulter.com and select "go to IR" under Investor Relations and find the call listed under "What's Ahead." The webcast will be archived for future on-demand replay.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies, (including reagent test k
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
2. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
3. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
4. Beckman Coulter to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Beckman Coulter to Host Annual Business Review
6. Beckman Coulter to Present at Upcoming Healthcare Conferences
7. Beckman Coulter to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
8. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
9. Beckman Coulter to Present at the Oppenheimer Annual Healthcare Conference
10. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
11. Beckman Coulter Investor Events Second Half of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets  has announced ... Mass Spectrometer Industry Report 2014" report to their ... Mass Spectrometer Industry Report 2014 is a professional and ... isotope ratio mass spectrometer industry. The report ... classifications, applications and industry chain structure. The isotope ratio ...
(Date:8/27/2014)... Palm Beach County, Florida (PRWEB) August 27, 2014 ... & Company Inc. (SCI) is announcing the creation ... board’s priority is to take the SCI’s philosophy ... insuring the company’s research and development actions are ... interpretations. , This new Scientific Advisory Board provides ...
(Date:8/27/2014)... According to the 2013 Raw Material and ... and feel of markets for raw materials and ingredient ... push for more branded, science-backed products.” , Natural products ... growth in the last decade as consumers increasingly demand ... to fit a more ‘wellness’ lifestyle approach. Due ...
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
Breaking Biology Technology:Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Sept. 23 S*BIO Pte Ltd today announced ... will support the continued development of S*BIO,s clinical ... reflects the international investment community,s strong interest in ... clinical development and the quality of our various ...
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of results from a randomized Phase 2 trial ... results showed a survival benefit with the investigational ... cancer. The median overall survival for patients who ...
Cached Biology Technology:S*BIO Announces US$5 Million Investment by Mitsui Ventures 2S*BIO Announces US$5 Million Investment by Mitsui Ventures 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 2OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 3OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 5
(Date:8/27/2014)... -- When we want to listen carefully to someone, ... second thing we do is stop moving altogether. This ... generated by our own movements. , This interplay between ... the brain. Indeed, indirect evidence has long suggested that ... the auditory cortex, which gives rise to our conscious ...
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- The IEEE Engineering in ... th Annual International Conference (EMBC,14), this year being ... Chicago, Illinois , from Tuesday, August ... leaders, students, and industry professionals in science, medicine, and ... http://photos.prnewswire.com/prnh/20140827/140333 This year,s conference ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... July, 2009 Johnson & Johnson today announced that ... Biology at the Max Planck Institute of Biochemistry in ... including Herceptin (trastuzumab) , is the winner of the ... An independent committee of world-renowned scientists selected Dr. Ullrich, ...
... European Molecular Biology Laboratory,s European Bioinformatics Institute (EMBL-EBI) have ... which could accelerate research into treatments for H1N1 flu ... of curated life science Web Services, is being officially ... International Conference on Intelligent Systems for Molecular Biology and ...
... the Department of Science Education-Biology at the University of ... of the desert rhubarb, which enables it to harvest ... for a plant in this region based on the ... first example of a self-irrigating plant worldwide. The ...
Cached Biology News:Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2New e-science service could accelerate cancer research 2Desert rhubarb -- a self-irrigating plant 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: